NAD+ / MOTS-c / 5-Amino-1MQ blend
A supplier blend of NAD+, MOTS-c and 5-Amino-1MQ in one vial, sold for metabolic and mitochondrial support.
Regulatory status: Not a medicine. None of the three is approved for this use and the combination is unstudied.
Default vial
100 mg
Default mix
3 mL
Reported range
Varies with the blend ratio
Draw (U-100)
15 u
Three metabolic compounds in one vial, each with its own entry. 5-Amino-1MQ is not a peptide. The components have very different typical doses, so the blend ratio decides everything — read the COA.
Where these numbers come from
No human dosing trial defines a dose for this compound. The numbers here are the values community calculators pre-fill — reference only. The three components have very different typical doses, so the blend ratio determines the dose of each — read the COA before using any figure here.
Reviewed October 2026
What it is
- Three compounds in a single vial, each with its own Pep-Tidy entry.
- 5-Amino-1MQ is not a peptide — it is a small-molecule NNMT inhibitor.
- Their typical individual doses differ by orders of magnitude, which makes the blend ratio decisive rather than incidental.
- Investigational components only.
How it is described to act
- 1
Given as one subcutaneous injection containing all three.
- 2
Each component behaves as it does alone.
- 3
The rationale offered is converging effects on mitochondrial and metabolic pathways; nothing published tests the combination.
- 4
No outcome has been measured for it.
What the research has looked at
What the research covers
- The published work studies each separately — see the NAD+, MOTS-c and 5-Amino-1MQ entries.
- No published study tests the three together.
Why the ratio matters more here
- NAD+ is typically discussed in tens or hundreds of milligrams, while the peptide component is discussed in micrograms.
- A blend ratio that makes one component a sensible dose can make another far too little or far too much. Read the certificate of analysis.
Strength of evidence: Preclinical evidence only
No study tests this combination; the components have preclinical research only.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- A blend is several compounds at once, so an adverse effect cannot be traced to any one of them. Running components separately first is the only way to know which does what.
- Ratios are set by the supplier, not by any standard, so two vials with the same name can contain quite different amounts.
- The safety of the combination has not been studied. What is known, where anything is known, applies to each compound on its own.
- There are no combined pharmacokinetic or toxicity data for any of these blends, so interaction risk is unquantified.
- The FDA's 2026 compounding-committee briefing on BPC-157 documented adverse-event reports and gaps in impurity characterisation for that single peptide.
- Sterility, identity and concentration of multi-peptide compounded vials vary by supplier; only a current third-party Certificate of Analysis can confirm what a vial actually contains.
References
There are none. A search of the published literature returns no studies of this compound — no human trials, no animal work, no cell studies. Anything claimed about it elsewhere is not drawn from published research on this molecule.
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
NAD+ / MOTS-c / 5-Amino-1MQ blend questions people ask
How do you reconstitute NAD+ / MOTS-c / 5-Amino-1MQ blend?
A common starting point for a 100 mg vial of NAD+ / MOTS-c / 5-Amino-1MQ blend is 3 mL of bacteriostatic water, which gives 33.33 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of NAD+ / MOTS-c / 5-Amino-1MQ blend is one dose?
At 33.33 mg per mL, that works out to about 15 units on a U-100 insulin syringe for a 5000 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for NAD+ / MOTS-c / 5-Amino-1MQ blend?
Published and community sources describe Varies with the blend ratio, subcutaneous, every 3 days, typically run 4 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should NAD+ / MOTS-c / 5-Amino-1MQ blend be stored?
Lyophilized NAD+ / MOTS-c / 5-Amino-1MQ blend vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.